Eli Lilly announced it will buy Merida Biosciences for up to $2.88 billion in cash to expand its treatments for immune-related and allergic diseases. Merida's lead drug candidate targets autoimmune disorders like Graves' disease and thyroid eye disease, showing promising early results. The acquisition is part of Lilly's strategy to diversify beyond obesity and diabetes drugs. The deal is expected to close in Q4 2026, with Lilly paying an upfront amount plus milestone-based payments.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
